Literature DB >> 17179970

Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design.

D Lammertse1, M H Tuszynski, J D Steeves, A Curt, J W Fawcett, C Rask, J F Ditunno, M G Fehlings, J D Guest, P H Ellaway, N Kleitman, A R Blight, B H Dobkin, R Grossman, H Katoh, A Privat, M Kalichman.   

Abstract

The International Campaign for Cures of Spinal Cord Injury Paralysis established a panel tasked with reviewing the methodology for clinical trials for spinal cord injury (SCI), and making recommendations on the conduct of future trials. This is the fourth of four papers. Here, we examine the phases of a clinical trial program, the elements, types, and protocols for valid clinical trial design. The most rigorous and valid SCI clinical trial would be a prospective double-blind randomized control trial utilizing appropriate placebo control subjects. However, in specific situations, it is recognized that other trial procedures may have to be considered. We review the strengths and limitations of the various types of clinical trials with specific reference to SCI. It is imperative that the design and conduct of SCI clinical trials should meet appropriate standards of scientific inquiry to insure that meaningful conclusions about efficacy and safety can be achieved and that the interests of trial subjects are protected. We propose these clinical trials guidelines for use by the SCI clinical research community.

Entities:  

Mesh:

Year:  2006        PMID: 17179970      PMCID: PMC4106695          DOI: 10.1038/sj.sc.3102010

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  20 in total

Review 1.  Biomarkers and surrogate markers: an FDA perspective.

Authors:  Russell Katz
Journal:  NeuroRx       Date:  2004-04

Review 2.  Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures.

Authors:  J D Steeves; D Lammertse; A Curt; J W Fawcett; M H Tuszynski; J F Ditunno; P H Ellaway; M G Fehlings; J D Guest; N Kleitman; P F Bartlett; A R Blight; V Dietz; B H Dobkin; R Grossman; D Short; M Nakamura; W P Coleman; M Gaviria; A Privat
Journal:  Spinal Cord       Date:  2006-12-19       Impact factor: 2.772

Review 3.  Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics.

Authors:  M H Tuszynski; J D Steeves; J W Fawcett; D Lammertse; M Kalichman; C Rask; A Curt; J F Ditunno; M G Fehlings; J D Guest; P H Ellaway; N Kleitman; P F Bartlett; A R Blight; V Dietz; B H Dobkin; R Grossman; A Privat
Journal:  Spinal Cord       Date:  2006-12-19       Impact factor: 2.772

4.  Oscillating field stimulation for complete spinal cord injury in humans: a phase 1 trial.

Authors:  Scott Shapiro; Richard Borgens; Robert Pascuzzi; Karen Roos; Michael Groff; Scott Purvines; Richard Ben Rodgers; Shannon Hagy; Paul Nelson
Journal:  J Neurosurg Spine       Date:  2005-01

5.  Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.

Authors:  D D Cardenas; J Ditunno; V Graziani; A B Jackson; D Lammertse; P Potter; M Sipski; R Cohen; A R Blight
Journal:  Spinal Cord       Date:  2006-06-13       Impact factor: 2.772

6.  Omental transposition in chronic spinal cord injury.

Authors:  G L Clifton; W H Donovan; M M Dimitrijevic; S J Allen; A Ku; J R Potts; F G Moody; C Boake; A M Sherwood; J V Edwards
Journal:  Spinal Cord       Date:  1996-04       Impact factor: 2.772

7.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

8.  Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results.

Authors:  Nachshon Knoller; Gustavo Auerbach; Valentin Fulga; Gabriel Zelig; Josef Attias; Ronit Bakimer; Jonathan B Marder; Eti Yoles; Michael Belkin; Michal Schwartz; Moshe Hadani
Journal:  J Neurosurg Spine       Date:  2005-09

9.  Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.

Authors:  P J Potter; K C Hayes; J L Segal; J T Hsieh; S R Brunnemann; G A Delaney; D S Tierney; D Mason
Journal:  J Neurotrauma       Date:  1998-10       Impact factor: 5.269

Review 10.  Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials.

Authors:  J W Fawcett; A Curt; J D Steeves; W P Coleman; M H Tuszynski; D Lammertse; P F Bartlett; A R Blight; V Dietz; J Ditunno; B H Dobkin; L A Havton; P H Ellaway; M G Fehlings; A Privat; R Grossman; J D Guest; N Kleitman; M Nakamura; M Gaviria; D Short
Journal:  Spinal Cord       Date:  2006-12-19       Impact factor: 2.772

View more
  59 in total

Review 1.  A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury.

Authors:  Brian K Kwon; Elena B Okon; Eve Tsai; Michael S Beattie; Jacqueline C Bresnahan; David K Magnuson; Paul J Reier; Dana M McTigue; Phillip G Popovich; Andrew R Blight; Martin Oudega; James D Guest; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-10-18       Impact factor: 5.269

Review 2.  The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury.

Authors:  Andrew R Blight; Jane Hsieh; Armin Curt; James W Fawcett; James D Guest; Naomi Kleitman; Shekar N Kurpad; Brian K Kwon; Daniel P Lammertse; Norbert Weidner; John D Steeves
Journal:  Spinal Cord       Date:  2019-04-08       Impact factor: 2.772

3.  The evolution of walking-related outcomes over the first 12 weeks of rehabilitation for incomplete traumatic spinal cord injury: the multicenter randomized Spinal Cord Injury Locomotor Trial.

Authors:  B Dobkin; H Barbeau; D Deforge; J Ditunno; R Elashoff; D Apple; M Basso; A Behrman; S Harkema; M Saulino; M Scott
Journal:  Neurorehabil Neural Repair       Date:  2007 Jan-Feb       Impact factor: 3.919

Review 4.  Common data elements for spinal cord injury clinical research: a National Institute for Neurological Disorders and Stroke project.

Authors:  F Biering-Sørensen; S Alai; K Anderson; S Charlifue; Y Chen; M DeVivo; A E Flanders; L Jones; N Kleitman; A Lans; V K Noonan; J Odenkirchen; J Steeves; K Tansey; E Widerström-Noga; L B Jakeman
Journal:  Spinal Cord       Date:  2015-02-10       Impact factor: 2.772

Review 5.  Application of electrophysiological measures in spinal cord injury clinical trials: a narrative review.

Authors:  Michèle Hubli; John L K Kramer; Catherine R Jutzeler; Jan Rosner; Julio C Furlan; Keith E Tansey; Martin Schubert
Journal:  Spinal Cord       Date:  2019-07-23       Impact factor: 2.772

6.  Perseverance is required!

Authors:  Armin Curt
Journal:  Spinal Cord       Date:  2019-04-08       Impact factor: 2.772

7.  Experimental Treatments for Spinal Cord Injury: What you Should Know.

Authors:  Vieri Failli; Naomi Kleitman; Daniel P Lammertse; Jane T C Hsieh; John D Steeves; James W Fawcett; Mark H Tuszynski; Armin Curt; Michael G Fehlings; James D Guest; Andrew R Blight
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

Review 8.  A mapping review of randomized controlled trials in the spinal cord injury research literature.

Authors:  Amanda McIntyre; Brooke Benton; Shannon Janzen; Jerome Iruthayarajah; Joshua Wiener; Janice J Eng; Robert Teasell
Journal:  Spinal Cord       Date:  2018-06-14       Impact factor: 2.772

Review 9.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

10.  Minimizing errors in acute traumatic spinal cord injury trials by acknowledging the heterogeneity of spinal cord anatomy and injury severity: an observational Canadian cohort analysis.

Authors:  Marcel F Dvorak; Vanessa K Noonan; Nader Fallah; Charles G Fisher; Carly S Rivers; Henry Ahn; Eve C Tsai; A G Linassi; Sean D Christie; Najmedden Attabib; R John Hurlbert; Daryl R Fourney; Michael G Johnson; Michael G Fehlings; Brian Drew; Christopher S Bailey; Jérôme Paquet; Stefan Parent; Andrea Townson; Chester Ho; B C Craven; Dany Gagnon; Deborah Tsui; Richard Fox; Jean-Marc Mac-Thiong; Brian K Kwon
Journal:  J Neurotrauma       Date:  2014-07-08       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.